Pfizer

Pfizer P/B

The P/B (Price-to-Book Ratio) of Pfizer (PFIZER.NS) as of Sep 28, 2026 is 5.23. In the previous year, P/B (Price-to-Book Ratio) was 6.14 — a change of -14.75% (lower).

P/B

5.23

YoY

-14.75%

Last updated:

P/B (Price-to-Book Ratio) of Pfizer is 2026 5.23 . P/B (Price-to-Book Ratio) of Pfizer was 2025 6.14 . It decreases by -14.75% lower compared to the previous year.

The Pfizer P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
8.22 INR
Jan 1, 2019
7.33 INR
Jan 1, 2020
6.50 INR
Jan 1, 2021
9.22 INR
Jan 1, 2022
7.70 INR
Jan 1, 2023
6.88 INR
Jan 1, 2024
6.14 INR
Jan 1, 2025
5.23 INR
The Pfizer P/B history
YEARP/BYoY
5.23-14.75%
6.14-10.80%
6.88-10.69%
7.70-16.46%
9.22+41.89%
6.50-11.31%
7.33-10.90%
8.22-9.85%
9.12-10.56%
10.20-11.19%
11.48-65.74%
33.51—
Access this data via the Eulerpool API

Pfizer Stock analysis

What does Pfizer do? Pfizer Ltd is a global biopharmaceutical company based in New York City, USA. The company was founded in 1849 by cousins Charles Pfizer and Charles Erhart, and has achieved numerous milestones in the pharmaceutical industry during its 170-year history. Pfizer's business model is based on the research, development, production, and distribution of innovative drugs and vaccines for a variety of diseases. With a diverse portfolio of products, the company's range extends from drugs for cancer, inflammation, and immunology to neurological and cardiology conditions. Pfizer is a global leader in the development of cancer drugs and has achieved groundbreaking research successes in recent years. Key divisions of the company include oncology, pain management, cardiology, and neurology. Pfizer places great emphasis on putting patients and their needs at the center and works closely with medical professionals, patient groups, and authorities to ensure the best possible patient care. Pfizer is a leading provider of vaccines and has achieved significant breakthroughs in the development of COVID-19 vaccines in recent years. In December 2020, the company was one of the first worldwide to bring a vaccine against the coronavirus to market, making a significant contribution to the fight against the pandemic. In addition to drug research and development, Pfizer is also heavily involved in corporate social responsibility. The company is committed to sustainable development and continuously works to reduce its carbon footprint. The Pfizer Foundation also supports numerous nonprofit organizations and projects in the areas of health, education, and environmental protection. Among Pfizer's most well-known products are medications such as Viagra, Lipitor, and Lyrica, as well as the COVID-19 vaccine Comirnaty. Pfizer has offices in over 150 countries and employs over 90,000 people worldwide. Like any global company, Pfizer faces challenges. The company is often criticized for high drug prices and the availability of medications in developing countries. However, Pfizer actively advocates for access to affordable healthcare and delivers drugs and vaccines to all regions of the world. Overall, Pfizer is a company of great importance in the global healthcare industry. Through its research and development of innovative drugs and vaccines, the company contributes to improving the quality of life for millions of people worldwide. Pfizer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pfizer stock

P/B (Price-to-Book Ratio) of Pfizer is 5.23 in 2026.

P/B (Price-to-Book Ratio) of Pfizer changed from 6.14 to 5.23, representing a -14.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Pfizer since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Pfizer with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Pfizer

All Key Metrics — Pfizer